Reproducibility of assays for influenza vaccine immunogenicity determination: Progress towards consistency

Expert Review of Vaccines

Volumn 11, Issue 8, 2012, Pages 881-883

  Wagner, Ralf ^a   Pfleiderer, Michael ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

immunogenicity; influenza vaccine; reproducibility; serological assays

Indexed keywords

INFLUENZA VACCINE;

DRUG DETERMINATION; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VACCINATION; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SEROLOGY; STANDARDIZATION;

ANTIBODIES, VIRAL; CLINICAL TRIALS AS TOPIC; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEUTRALIZATION TESTS; PANDEMICS; REPRODUCIBILITY OF RESULTS; VIRAL LOAD;

EID: 84866715621     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.62     Document Type: Review

References (15)

1. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res. 103(1-2), 91-95 (2004).
2. Kayali G, Setterquist SF, Capuano AW, Myers KP, Gill JS, Gray GC. Testing human sera for antibodies against avian influenza viruses: horse RBC hemagglutination inhibition vs. microneutralization assays. J. Clin. Virol. 43(1), 73-78 (2008).
3. Stephenson I, Heath A, Major D et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerging Infect. Dis. 15(8), 1252-1259 (2009).
4. Russell SM, McCahon D, Beare AS. A single radial haemolysis technique for the measurement of influenza antibody. J. Gen. Virol. 27(1), 1-10 (1975).
5. Zambon MC. Laboratory diagnosis of influenza. In: Influenza. Nicholson KG, Webster RG, Hay AJ (Eds.). Blackwell Publishing, Oxford, UK, 123-156 (1997).
6. Eichelberger M, Golding H, Hess M et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 26(34), 4299-4303 (2008).
7. Stephenson I, Das RG, Wood JM, Katz JM. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 25(20), 4056-4063 (2007).
8. Wood JM, Montomoli E, Newman RW, Daas A, Buchheit KH, Terao E. Collaborative study on influenza vaccine clinical trial serology-part 2: reproducibility study. Pharmeur. Bio Sci. Notes 2011(1), 36-54 (2011).
9. Wood JM, Major D, Heath A et al. Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard. Vaccine 30(2), 210-217 (2012).
10. Wagner R, Göpfert C, Hammann J et al. Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines-an effective EU regulatory approach. Vaccine 30(27), 4113-4122 (2012).
11. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. In: Laboratory Correlates of Immunity to Influenza-a Reassessment. Brown F, Haaheim LR, Schild GC (Eds). Karger, Basel, Switzerland, 63-73 (2003).
12. Wood JM, Newman RW, Ploss K. The use of correlates of immunity in European Union licensing of influenza vaccines. In: Laboratory Correlates of Immunity to Influenza-a Reassessment. Brown F, Haaheim LR, Schild GC (Eds). Karger, Basel, Switzerland, 9-16 (2003).
13. Epstein SL, Price GE. Cross-protective immunity to influenza A viruses. Expert Rev. Vaccines 9(11), 1325-1341 (2010).
14. Lambert LC, Fauci AS. Influenza vaccines for the future. N. Engl. J. Med. 363(21), 2036-2044 (2010).
15. Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine 26(Suppl. 4), D41-D44 (2008).